Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases, including MET and VEGFR2. In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. Our studies aimed to determine the expression of cabozantinib targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Holly M., Ruppender, Nazanin, Zhang, Xiaotun, Brown, Lisha G., Gross, Ted S., Morrissey, Colm, Gulati, Roman, Vessella, Robert L., Schimmoller, Frauke, Aftab, Dana T., Corey, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808282/
https://www.ncbi.nlm.nih.gov/pubmed/24205338
http://dx.doi.org/10.1371/journal.pone.0078881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808282/
https://www.ncbi.nlm.nih.gov/pubmed/24205338
http://dx.doi.org/10.1371/journal.pone.0078881

Ejemplares similares